Research
What Is the KLOW Peptide? KPV + GHK-Cu + BPC-157 + TB-500 Blend Overview
The KLOW peptide is the research-market name for a four-component blend combining KPV, GHK-Cu, BPC-157, and TB-500 in a single lyophilized vial — the letters of the name index its components. It extends the three-peptide GLOW blend by adding KPV, bringing the preparation to 80 mg of total peptide content. Each of the four components has its own independent research literature; the blend exists because the four are repeatedly studied in overlapping dermal, matrix-remodeling, and cell-migration models, and a co-formulated vial fixes their ratio for combination assay designs.
What the blend contains
| Component | Type | Class of published research |
|---|---|---|
| KPV | Tripeptide (Lys-Pro-Val), C-terminal fragment of α-MSH | Inflammation-pathway models |
| GHK-Cu | Tripeptide–copper(II) complex (Gly-His-Lys·Cu) | Matrix remodeling, copper biology |
| BPC-157 | Pentadecapeptide (15 residues) | Cytoprotection, signaling models |
| TB-500 | Peptide associated with thymosin β4 literature | Actin dynamics, cell migration |
Total peptide content is 80 mg per vial as supplied; the exact per-component specification is listed on the product page. Analytically, a four-component blend is the most demanding preparation in the catalog — four identities to confirm, four peak families to resolve — a point covered below.
KPV — the fragment that names the blend
KPV is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH), corresponding to its last three residues (Lys-Pro-Val, ~342 Da). What makes this fragment interesting in the published literature is that it retains much of the parent hormone's activity in inflammation-pathway models while being too short to activate the melanocortin receptors responsible for α-MSH's pigmentary signaling — a clean example of how fragment work separates one activity of a parent molecule from another.
Mechanistic studies have examined KPV's inhibition of NF-κB activation in epithelial and immune cell lines, and a body of work has characterized its cellular uptake through the peptide transporter PepT1 — a transport route that made it a model compound for intestinal-epithelium research designs (Dalmasso G, et al. Gastroenterology. 2008;134(1):166–178; Brzoska T, et al. Endocr Rev. 2008;29(5):581–602). A dedicated overview is at KPV.
GHK-Cu — the copper complex
GHK-Cu is the tripeptide Gly-His-Lys complexed with a copper(II) ion (~402 Da as the complex). First identified in human plasma, the free tripeptide has an unusually high affinity for Cu²⁺, and most of its published biology is inseparable from that copper coordination. The in vitro literature concentrates on modulation of extracellular-matrix biology: collagen and glycosaminoglycan synthesis in fibroblast cultures, regulation of matrix metalloproteinases and their inhibitors, and copper delivery into cells — copper being a cofactor for enzymes central to matrix cross-linking, including lysyl oxidase (Pickart L, Margolina A. Int J Mol Sci. 2018;19(7):1987). Gene-profiling work has additionally cataloged broad transcriptional responses of fibroblasts to the complex. The dedicated overview is at GHK-Cu.
BPC-157 and TB-500 — the shared core
The remaining two components are the pairing covered in depth in the Wolverine blend overview: BPC-157, the stable gastric-derived pentadecapeptide whose literature centers on nitric-oxide modulation, growth-factor-pathway expression, and cytoprotection models; and TB-500, the research peptide associated with the thymosin β4 actin-binding literature and its cell-migration mechanics. Dedicated overviews: BPC-157 · TB-500. The same identity caveat applies here as in any TB-500-containing preparation: market naming for that component is inconsistent across the industry (full-length thymosin β4 versus its active fragment), and mass-spectrometry identity testing is what resolves it for a given lot.
Why these four travel together
Read as a set, the four literatures converge on the biology of tissue in flux — from four different mechanistic directions. GHK-Cu's published work is about the extracellular matrix itself (synthesis, remodeling enzymes, copper chemistry); the thymosin β4 axis is about the actin machinery cells migrate with; BPC-157's is about signaling-level modulation in the same cell types; KPV's is about the inflammatory tone of the environment those cells operate in. In vitro programs studying fibroblast behavior, matrix turnover, or epithelial models can therefore use one co-formulated preparation to interrogate matrix, migration, signaling, and inflammation arms in a fixed ratio — which is the design logic behind blending, and why the KLOW name recurs across dermal-model research discussions. Some sources describe the same four-component preparation as a "KLOW blend peptide"; the terms refer to the same formulation.
Analytical considerations for a four-component blend
- Four identity confirmations. Mass spectrometry must resolve four expected masses spanning roughly 342 Da (KPV) to the TB-500 component — the widest identity spread of any catalog preparation.
- Peak assignment. An HPLC chromatogram of the blend contains each component's peak family; purity assessment requires assigning peaks to components rather than reading a single main-peak percentage.
- Copper chemistry. GHK-Cu contributes a metal complex to the mixture — its characterization differs from a plain peptide's, and the copper coordination is part of what identity means for that component.
- Ratio verification. A fixed-ratio blend is only useful to a research design if the ratio is confirmed per lot.
HEEZ Research supplies KLOW as a lyophilized preparation with independent third-party HPLC and mass-spectrometry testing; Certificates of Analysis are published on product pages as testing is completed — review the report before you order. Current specifications are on the KLOW product page.
Frequently asked questions
What is the KLOW peptide?
KLOW is the research-market name for a four-peptide blend — KPV, GHK-Cu, BPC-157, and TB-500 — co-formulated in one lyophilized vial at 80 mg total peptide content. The name's letters index the components. Each component has its own independent research literature.
How does KLOW differ from the GLOW blend?
KLOW is GLOW plus KPV. GLOW combines GHK-Cu, BPC-157, and TB-500; KLOW adds the α-MSH-derived tripeptide KPV as a fourth component, extending the blend's coverage into inflammation-pathway models.
What is KPV and why is it in the blend?
KPV is the C-terminal tripeptide fragment of α-MSH (Lys-Pro-Val). In published models it retains the parent hormone's activity in inflammation pathways — NF-κB inhibition in epithelial and immune cell lines — without the receptor activity behind α-MSH's pigmentary signaling, adding an inflammation-arm probe to the blend's matrix, migration, and signaling components.
What should a Certificate of Analysis show for KLOW?
Mass-spectrometry identity confirmation for all four components, HPLC purity with peaks assigned per component, and evidence on the component ratio. Identity testing is particularly informative for the TB-500 component, where industry naming is inconsistent.
Is "KLOW blend peptide" the same thing as the KLOW peptide?
Yes — both phrases refer to the same four-component KPV + GHK-Cu + BPC-157 + TB-500 preparation.
Related research
References
- Dalmasso G, et al. Gastroenterology. 2008;134(1):166–178. PubMed 18061177
- Brzoska T, et al. Endocr Rev. 2008;29(5):581–602. PubMed 18612139
- Pickart L, Margolina A. Int J Mol Sci. 2018;19(7):1987. PubMed 29986520
- Sikiric P, et al. Curr Pharm Des. 2018;24(18):1990–2001. PubMed 29667553
- Goldstein AL, et al. Ann N Y Acad Sci. 2010;1194:118–124. PubMed 20536458
This article is a research reference. HEEZ Research products are supplied for in vitro laboratory research only — not for human or veterinary use.
Last reviewed August 2026 by the HEEZ Research team.
↑ Back to top